STERIS Management
Management Kriterienprüfungen 4/4
STERIS CEO ist Dan Carestio , ernannt in Jul 2021, hat eine Amtszeit von 5.08 Jahren. Die jährliche Gesamtvergütung beträgt $11.51M , bestehend aus 9.5% Gehalt und 90.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.065% der Aktien des Unternehmens, im Wert von $15.12M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.1 Jahre bzw. 5.6 Jahre.
Wichtige Informationen
Dan Carestio
Geschäftsführender
US$11.5m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 9.52% |
| Amtszeit als Geschäftsführer | 5.1yrs |
| Eigentum des Geschäftsführers | 0.07% |
| Durchschnittliche Amtszeit des Managements | 6.1yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 5.6yrs |
Jüngste Management Updates
Recent updates
Seeking Alpha • Jul 27
Steris: A Good Moment To Buy Shares In This Sterilization Leader
Summary Steris provides infection prevention products and sterilization services to medical clientele (such as hospitals, outpatient surgery centers, and pharmaceutical companies). Steris has increased its dividend for 21 consecutive years. The 10-year dividend growth rate of 9.6% is strong, but more recent dividend raises have actually been over 10%. STE has a great financial position. Its long-term debt/equity ratio is 0.3, while the interest coverage ratio is over 18. The P/E ratio is now down to 26.6. That’s far lower than its five-year average of 46.8. Read the full article on Seeking Alpha
Narrative-Update • Jun 24
STE: Share Repurchases And Recurring Platform Earnings Will Support Future Upside
Analysts have made a small adjustment to their price target on STERIS, keeping fair value around $256.86 while fine-tuning assumptions on discount rate, revenue growth, profit margin and future P/E to reflect updated expectations for the business. What's in the News STERIS reported fiscal 2026 adjusted EPS of $10.17 compared with $9.22 a year earlier and total revenue of $5.94b, with broad-based revenue growth led by healthcare and faster percentage gains in Life Sciences.Narrative-Update • Jun 04
STE: Share Repurchases And Earnings Outlook Will Support Future Upside
Analysts have trimmed their price target for STERIS to $256.86 from $279.29, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that collectively point to a lower fair value estimate. What's in the News STERIS announced a share repurchase program authorizing the company to buy back up to US$1,000 million of its ordinary shares.Narrative-Update • May 11
STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside
Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.Narrative-Update • Apr 26
STE: Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).Narrative-Update • Apr 11
STE: Completed Buyback And Stable Assumptions Will Support Future Upside
Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.Narrative-Update • Mar 28
STE: Completed Buyback And Refined Assumptions Will Support Future Upside
Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.Analyseartikel • Mar 24
Is There Now An Opportunity In STERIS plc (NYSE:STE)?
STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...Narrative-Update • Mar 11
STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside
Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.Narrative-Update • Feb 25
STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside
Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.Narrative-Update • Feb 10
STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View
Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.Narrative-Update • Jan 27
STE: Share Repurchases And Stable Outlook Will Support A Fair View
Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).Narrative-Update • Jan 10
STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook
Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.Analyseartikel • Jan 09
Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Analyseartikel • Dec 26
Earnings Tell The Story For STERIS plc (NYSE:STE)
With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...Narrative-Update • Dec 23
STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook
Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).Narrative-Update • Dec 09
STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook
Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).Narrative-Update • Nov 25
STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance
Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.Narrative-Update • Nov 07
STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value
Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.Analyseartikel • Oct 27
Is STERIS (NYSE:STE) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative-Update • Sep 05
Healthcare Demand And Facility Expansion Will Create Value
With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.Analyseartikel • Aug 28
Calculating The Fair Value Of STERIS plc (NYSE:STE)
Key Insights STERIS' estimated fair value is US$227 based on 2 Stage Free Cash Flow to Equity With US$249 share price...Seeking Alpha • Mar 22
Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'
Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking AlphaSeeking Alpha • Nov 18
Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'
Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking AlphaSeeking Alpha • Sep 16
Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued
Summary I reiterate a 'Hold' rating for Steris stock with a fair value of $220 per share, citing strong healthcare growth and overvaluation concerns. The divestiture of the dental business and acquisition of Surgical Instrumentation assets will allow Steris to focus on core healthcare and AST businesses. Steris reported 5.4% organic revenue growth and 7% adjusted EPS growth, driven by a 7.2% increase in AST business and strong healthcare performance. Despite strategic moves, cautious outlook on healthcare capital equipment spending due to high-interest rates supports maintaining a 'Hold' rating. Read the full article on Seeking AlphaAnalyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$805m |
| Mar 31 2026 | US$12m | US$1m | US$782m |
| Dec 31 2025 | n/a | n/a | US$709m |
| Sep 30 2025 | n/a | n/a | US$689m |
| Jun 30 2025 | n/a | n/a | US$648m |
| Mar 31 2025 | US$11m | US$1m | US$610m |
| Dec 31 2024 | n/a | n/a | US$617m |
| Sep 30 2024 | n/a | n/a | US$591m |
| Jun 30 2024 | n/a | n/a | US$561m |
| Mar 31 2024 | US$10m | US$1m | US$551m |
| Dec 31 2023 | n/a | n/a | US$1b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$576m |
| Mar 31 2023 | US$8m | US$970k | US$557m |
| Dec 31 2022 | n/a | n/a | -US$28m |
| Sep 30 2022 | n/a | n/a | -US$8m |
| Jun 30 2022 | n/a | n/a | US$377m |
| Mar 31 2022 | US$6m | US$767k | US$285m |
| Dec 31 2021 | n/a | n/a | US$279m |
| Sep 30 2021 | n/a | n/a | US$250m |
| Jun 30 2021 | n/a | n/a | US$286m |
| Mar 31 2021 | US$3m | US$542k | US$397m |
| Dec 31 2020 | n/a | n/a | US$433m |
| Sep 30 2020 | n/a | n/a | US$424m |
| Jun 30 2020 | n/a | n/a | US$413m |
| Mar 31 2020 | US$2m | US$522k | US$408m |
Vergütung im Vergleich zum Markt: DanDie Gesamtvergütung ($USD11.51M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD14.43M).
Entschädigung vs. Einkommen: DanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Dan Carestio (53 yo)
5.1yrs
Amtszeit
US$11,508,522
Vergütung
Mr. Daniel A. Carestio, also known as Dan, serves as the Chief Executive Officer & President at STERIS plc since July 29, 2021. He had been Senior Vice President and Chief Operating Officer at STERIS plc s...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 5.1yrs | US$11.51m | 0.065% $ 15.1m | |
| Senior VP | 9.6yrs | US$3.19m | 0.014% $ 3.1m | |
| Senior VP | 13.1yrs | US$2.95m | 0.036% $ 8.4m | |
| SVP & Chief Human Resources Officer | 6.1yrs | US$2.07m | 0.014% $ 3.3m | |
| Senior VP & President of Healthcare | 7yrs | US$2.45m | 0.018% $ 4.1m | |
| Vice President of Investor Relations & Corporate Communications | no data | keine Daten | keine Daten | |
| VP, Chief Compliance & Quality Officer | no data | keine Daten | 0.0061% $ 1.4m | |
| Senior VP & GM of Life Sciences | 6.1yrs | keine Daten | 0.013% $ 2.9m | |
| Senior VP & GM of Dental | 5.2yrs | US$1.92m | keine Daten | |
| Senior VP & GM of AST | 2.5yrs | keine Daten | 0.012% $ 2.7m | |
| VP & Corporate Treasurer | 9yrs | keine Daten | 0.0064% $ 1.5m | |
| CEO Emeritus & Senior Advisor | 5.1yrs | US$1.16m | keine Daten |
6.1yrs
Durchschnittliche Betriebszugehörigkeit
58.5yo
Durchschnittliches Alter
Erfahrenes Management: Das Managementteam von STE ist erfahren und erfahren (durchschnittliche Amtszeit von 6.1 Jahren).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| President | 5.6yrs | US$11.51m | 0.065% $ 15.1m | |
| Independent Chairman of the Board | 21.1yrs | US$503.69k | 0.025% $ 5.8m | |
| Independent Director | 21.4yrs | US$349.74k | 0.0096% $ 2.2m | |
| Independent Director | 5.3yrs | US$342.24k | 0% $ 0 | |
| Independent Director | 8.3yrs | US$336.24k | 0.00030% $ 69.5k | |
| Independent Director | 1.1yrs | US$340.78k | keine Daten | |
| Independent Director | 6.1yrs | US$354.78k | 0.00060% $ 138.9k | |
| Independent Director | less than a year | US$76.99k | keine Daten | |
| Independent Director | 3.3yrs | US$343.74k | 0% $ 0 |
5.6yrs
Durchschnittliche Betriebszugehörigkeit
66yo
Durchschnittliches Alter
Erfahrener Vorstand: STEDie Vorstandsmitglieder gelten als erfahren (5.6 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/09 16:31 |
| Aktienkurs zum Tagesende | 2026/08/07 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
STERIS plc wird von 17 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Michael Polark | Baird |
| Erin Wilson Wright | BofA Global Research |
| David Turkaly | Citizens JMP Securities, LLC |